



## Clinical trial results:

### A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin's lymphoma (iNHL) – CHRONOS-3

#### Summary

EudraCT number	2013-003893-29
Trial protocol	IE PT DE ES BE LT HU AT DK FR BG LU GR SK IT RO
Global end of trial date	

#### Results information

Result version number	v2 (current)
This version publication date	20 July 2023
First version publication date	12 September 2021
Version creation reason	

#### Trial information

##### Trial identification

Sponsor protocol code	BAY80-6946/17067
-----------------------	------------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02367040
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Bayer AG
Sponsor organisation address	Kaiser-Wilhelm-Allee, Leverkusen, Germany, D-51368
Public contact	Therapeutic Area Head, Bayer AG, +49 30 300139003, clinical-trials-contact@bayer.com
Scientific contact	Therapeutic Area Head, Bayer AG, +49 30 300139003, clinical-trials-contact@bayer.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	31 August 2022
Is this the analysis of the primary completion data?	No
Global end of trial reached?	No

Notes:

## General information about the trial

Main objective of the trial:

To evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression-free survival (PFS) in patients with relapsed iNHL who have received one or more lines of treatment, including rituximab, and who either had a treatment-free interval of  $\geq$  12 months after completion of the last rituximab-containing treatment, or who are unwilling to receive chemotherapy/for whom chemotherapy is contraindicated on reason of age, comorbidities, and/or residual toxicity.

Protection of trial subjects:

The conduct of this clinical study met all local legal and regulatory requirements. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and the International Conference on Harmonization guideline E6: Good Clinical Practice. Before entering the study, the informed consent form was read by and explained to all subjects. Participating subjects signed informed consent form and could withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Only investigators qualified by training and experience were selected as appropriate experts to investigate the study drug.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	03 August 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 6
Country: Number of subjects enrolled	Australia: 9
Country: Number of subjects enrolled	Brazil: 28
Country: Number of subjects enrolled	Austria: 7
Country: Number of subjects enrolled	Belgium: 1
Country: Number of subjects enrolled	Bulgaria: 13
Country: Number of subjects enrolled	Chile: 8
Country: Number of subjects enrolled	China: 81
Country: Number of subjects enrolled	Colombia: 9
Country: Number of subjects enrolled	France: 17
Country: Number of subjects enrolled	Germany: 8
Country: Number of subjects enrolled	Greece: 11
Country: Number of subjects enrolled	Hong Kong: 2
Country: Number of subjects enrolled	Hungary: 18
Country: Number of subjects enrolled	Ireland: 5
Country: Number of subjects enrolled	Italy: 4

Country: Number of subjects enrolled	Japan: 37
Country: Number of subjects enrolled	Malaysia: 9
Country: Number of subjects enrolled	Mexico: 5
Country: Number of subjects enrolled	Philippines: 4
Country: Number of subjects enrolled	Portugal: 2
Country: Number of subjects enrolled	Poland: 15
Country: Number of subjects enrolled	Romania: 16
Country: Number of subjects enrolled	Russian Federation: 25
Country: Number of subjects enrolled	Singapore: 6
Country: Number of subjects enrolled	Slovakia: 2
Country: Number of subjects enrolled	South Africa: 2
Country: Number of subjects enrolled	Korea, Republic of: 13
Country: Number of subjects enrolled	Spain: 11
Country: Number of subjects enrolled	Taiwan: 15
Country: Number of subjects enrolled	Thailand: 6
Country: Number of subjects enrolled	Turkey: 26
Country: Number of subjects enrolled	Ukraine: 15
Country: Number of subjects enrolled	United States: 18
Country: Number of subjects enrolled	Viet Nam: 4
Worldwide total number of subjects	458
EEA total number of subjects	130

Notes:

---

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	255
From 65 to 84 years	197
85 years and over	6

## Subject disposition

### Recruitment

Recruitment details:

The study was conducted at multiple centers in North America, South America, South Africa, Europe, Asia, and Australia between 03 August 2015 (first subject first visit) and 17 December 2019 (last subject first visit). 31 August 2022 was the 2-year follow-up after the primary completion cut-off date for data reporting.

### Pre-assignment

Screening details:

Overall, 652 were screened and total of 458 subjects were randomized in a 2:1 ratio to study treatment: 307 subjects to copanlisib/rituximab and 151 subjects to placebo/rituximab.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Carer, Subject, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Copanlisib + Rituximab

Arm description:

Copanlisib (60 mg) was administered intravenously (IV) (over approximately 1 h) on Days 1, 8, and 15 of each 28-day cycle. Rituximab (375 mg/m<sup>2</sup>) was administered weekly during Cycle 1 on Days 1, 8, 15, and 22, and then on Day 1 of Cycles 3, 5, 7, and 9. Copanlisib was administered before rituximab.

Arm type	Experimental
Investigational medicinal product name	Copanlisib
Investigational medicinal product code	BAY80-6946
Other name	
Pharmaceutical forms	Concentrate for emulsion for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Copanlisib was supplied as lyophilized preparation in a 6 ml injection vial. The total amount of copanlisib per vial was 60 mg. The solution for IV infusions was obtained after reconstitution with normal saline solution. Dosing was administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib was administered before rituximab.

Investigational medicinal product name	Rituximab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Rituximab dose 375 mg/m<sup>2</sup> body surface weekly during Cycle 1 on Days 1, 8, 15 and 22, and then on Day 1 of Cycles 3, 5, 7 and 9. The solution for IV infusions was obtained after reconstitution of a calculated concentration of 1 to 4 mg/ml rituximab into an infusion bag containing sterile, pyrogen-free sodium chloride 9 mg/ml (0.9%) solution for injection or 5% D-Glucose in water.

<b>Arm title</b>	Placebo + Rituximab
------------------	---------------------

Arm description:

Placebo was administered intravenously (IV) (over approximately 1 h) on Days 1, 8, and 15 of each 28-day cycle. Rituximab (375 mg/m<sup>2</sup>) was administered weekly during Cycle 1 on Days 1, 8, 15, and 22, and then on Day 1 of Cycles 3, 5, 7, and 9. Placebo was administered before rituximab.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for emulsion for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Placebo was supplied as lyophilized preparation in a 6 ml injection vial. The developed placebo lyophilisate was equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing was administered on Days 1, 8 and 15 of each 28-day cycle. Placebo was administered before rituximab.

<b>Number of subjects in period 1</b>	Copanlisib + Rituximab	Placebo + Rituximab
Started	307	151
Received treatment	304	149
Completed	32	10
Not completed	275	141
Progressive disease – radiological progression	51	78
Adverse event, serious fatal	2	-
AE associated with clinical disease progression	1	3
Physician decision	2	8
Drug not administered	3	2
Randomized by mistake with study treatment	1	-
AE not associated clinical disease progression	114	11
Failure to meet continuation criteria	1	-
Progressive disease – clinical progression	6	6
Other reason: Covid-19 pandemic related	1	-
Consent withdrawn by subject	46	16
Patient decision	39	14
Non-compliance with study drug	1	-
Switching to other therapy	2	-
Lost to follow-up	1	1
Patient decision: COVID-19 pandemic related	1	-
Required procedure failed	1	-
Progressive disease	-	1
Lack of efficacy	1	-
Protocol deviation	1	-
Additional primary malignancy	-	1



## Baseline characteristics

### Reporting groups

Reporting group title	Copanlisib + Rituximab
-----------------------	------------------------

Reporting group description:

Copanlisib (60 mg) was administered intravenously (IV) (over approximately 1 h) on Days 1, 8, and 15 of each 28-day cycle. Rituximab (375 mg/m<sup>2</sup>) was administered weekly during Cycle 1 on Days 1, 8, 15, and 22, and then on Day 1 of Cycles 3, 5, 7, and 9. Copanlisib was administered before rituximab.

Reporting group title	Placebo + Rituximab
-----------------------	---------------------

Reporting group description:

Placebo was administered intravenously (IV) (over approximately 1 h) on Days 1, 8, and 15 of each 28-day cycle. Rituximab (375 mg/m<sup>2</sup>) was administered weekly during Cycle 1 on Days 1, 8, 15, and 22, and then on Day 1 of Cycles 3, 5, 7, and 9. Placebo was administered before rituximab.

Reporting group values	Copanlisib + Rituximab	Placebo + Rituximab	Total
Number of subjects	307	151	458
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	167	88	255
From 65-84 years	140	63	203
85 years and over	0	0	0
Age Continuous			
Units: years			
arithmetic mean	62.0	61.5	-
standard deviation	± 12.1	± 11.0	-
Sex: Female, Male			
Units: Participants			
Female	154	66	220
Male	153	85	238
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	3	4	7
Asian	125	50	175
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	4	1	5
White	164	89	253
More than one race	0	0	0
Unknown or Not Reported	11	7	18
Eastern cooperative oncology group (ECOG) Performance Status (PS)			
ECOG PS was measured in a scale from 0 (best) to grade 2, where 0=Fully active, able to carry on all pre-diseases performance without restriction, 1=Restricted in physically strenuous activity but			

ambulatory and able to carry out work of a light or sedentary nature, 2=Ambulatory and capable of all self-care but unable to carry out any work activities, up and about more than 50 percent (%) waking hours (h).

Units: Subjects			
0 – Fully active	182	95	277
1 – Restricted active	113	55	168
2 – Ambulatory and capable of all self-care	12	1	13
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	29	26	55
Not Hispanic or Latino	262	118	380
Unknown or Not Reported	16	7	23

## End points

### End points reporting groups

Reporting group title	Copanlisib + Rituximab
Reporting group description: Copanlisib (60 mg) was administered intravenously (IV) (over approximately 1 h) on Days 1, 8, and 15 of each 28-day cycle. Rituximab (375 mg/m <sup>2</sup> ) was administered weekly during Cycle 1 on Days 1, 8, 15, and 22, and then on Day 1 of Cycles 3, 5, 7, and 9. Copanlisib was administered before rituximab.	
Reporting group title	Placebo + Rituximab
Reporting group description: Placebo was administered intravenously (IV) (over approximately 1 h) on Days 1, 8, and 15 of each 28-day cycle. Rituximab (375 mg/m <sup>2</sup> ) was administered weekly during Cycle 1 on Days 1, 8, 15, and 22, and then on Day 1 of Cycles 3, 5, 7, and 9. Placebo was administered before rituximab.	
Subject analysis set title	Full analysis set (FAS)
Subject analysis set type	Full analysis
Subject analysis set description: All randomized subjects were included.	
Subject analysis set title	Safety analysis set (SAF)
Subject analysis set type	Safety analysis
Subject analysis set description: All FAS subjects with at least one intake of copanlisib/placebo or rituximab.	

### Primary: Progression free survival (PFS) based on independent central review.

End point title	Progression free survival (PFS) based on independent central review.
End point description: Progression-free survival (PFS) was defined as the time from randomization to progressive disease (PD) or death due to any cause, whichever was earlier according to the Lugano Classification and Response criteria in patients affected by Waldenström macroglobulinemia.	
End point type	Primary
End point timeframe: From first subject randomization up to approximately 7 years at data cut-off date	

End point values	Copanlisib + Rituximab	Placebo + Rituximab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	307	151		
Units: Months				
median (confidence interval 95%)				
At primary completion date	21.5 (17.8 to 33.0)	13.8 (10.2 to 17.5)		
At 2-year follow-up cut-off date	23.2 (19.4 to 33.0)	13.8 (10.8 to 17.5)		

### Statistical analyses

Statistical analysis title	Progression free survival (PFS)
----------------------------	---------------------------------

Statistical analysis description:

At 2-year follow-up cut-off date

Comparison groups	Copanlisib + Rituximab v Placebo + Rituximab
Number of subjects included in analysis	458
Analysis specification	Pre-specified
Analysis type	superiority <sup>[1]</sup>
P-value	= 0.000003 <sup>[2]</sup>
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.557
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.431
upper limit	0.722

Notes:

[1] - PFS was evaluated with the stratified log-rank test. HR and 95% CI were based on stratified Cox Regression Model.

[2] - 1-sided p-value

<b>Statistical analysis title</b>	Progression free survival (PFS)
-----------------------------------	---------------------------------

Statistical analysis description:

At primary completion date

Comparison groups	Copanlisib + Rituximab v Placebo + Rituximab
Number of subjects included in analysis	458
Analysis specification	Pre-specified
Analysis type	superiority <sup>[3]</sup>
P-value	= 0.000002 <sup>[4]</sup>
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.52
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.393
upper limit	0.688

Notes:

[3] - PFS was evaluated with the stratified log-rank test. HR and 95% CI were based on stratified Cox Regression Model.

[4] - 1-sided p-value

### **Secondary: Objective response rate (ORR)**

End point title	Objective response rate (ORR)
-----------------	-------------------------------

End point description:

Objective response rate (ORR) was defined as the percentage of subjects who have a best response rating over the whole duration of the study (i.e. until time of analysis of PFS) of complete response (CR) or partial response (PR) according to the Lugano Classification and for patients with Waldenström macroglobulinemia (WM) a response rating of CR, very good partial response (VGPR), PR, or minor response (MR) according to the Owen Criteria.

End point type	Secondary
----------------	-----------

End point timeframe:

From first subject randomization up to approximately 7 years at data cut-off date

<b>End point values</b>	Copanlisib + Rituximab	Placebo + Rituximab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	307	151		
Units: Percentage of subjects				
number (not applicable)				
At primary completion date	80.8	47.7		
At 2-year follow-up cut-off date	80.5	49.7		

## Statistical analyses

<b>Statistical analysis title</b>	Objective response rate (ORR)
Statistical analysis description: At 2-year follow-up cut-off date	
Comparison groups	Copanlisib + Rituximab v Placebo + Rituximab
Number of subjects included in analysis	458
Analysis specification	Pre-specified
Analysis type	superiority <sup>[5]</sup>
P-value	< 0.000001 <sup>[6]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in ORR
Point estimate	30.67
Confidence interval	
level	95 %
sides	2-sided
lower limit	21.63
upper limit	39.72

Notes:

[5] - P-value from Cochran-Mantel-Haenszel (CMH) test stratified

[6] - 1-sided p-value

<b>Statistical analysis title</b>	Objective response rate (ORR)
Statistical analysis description: At primary completion date	
Comparison groups	Copanlisib + Rituximab v Placebo + Rituximab
Number of subjects included in analysis	458
Analysis specification	Pre-specified
Analysis type	superiority <sup>[7]</sup>
P-value	< 0.000001 <sup>[8]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in ORR
Point estimate	32.99

Confidence interval	
level	95 %
sides	2-sided
lower limit	23.95
upper limit	42.03

Notes:

[7] - P-value from Cochran-Mantel-Haenszel (CMH) test stratified

[8] - 1-sided p-value

### Secondary: Complete response rate (CRR)

End point title	Complete response rate (CRR)
-----------------	------------------------------

End point description:

Complete response rate (CRR) was defined as the percentage of subjects who had a best response rating over the whole duration of the study (i.e., until the time of analysis of PFS) according to the Lugano Classification and for patients with Waldenström macroglobulinemia (WM) a response rating of Complete Response according to the Owen Criteria.

End point type	Secondary
----------------	-----------

End point timeframe:

From first subject randomization up to approximately 7 years at data cut-off date

End point values	Copanlisib + Rituximab	Placebo + Rituximab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	307	151		
Units: Percentage of subjects				
number (not applicable)				
At primary completion date	33.9	14.6		
At 2-year follow-up cut-off date	34.2	15.2		

### Statistical analyses

Statistical analysis title	Complete response rate (CRR)
----------------------------	------------------------------

Statistical analysis description:

At 2-year follow-up cut-off date

Comparison groups	Copanlisib + Rituximab v Placebo + Rituximab
Number of subjects included in analysis	458
Analysis specification	Pre-specified
Analysis type	superiority <sup>[9]</sup>
P-value	= 0.000001 <sup>[10]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in CRR
Point estimate	18.92
Confidence interval	
level	95 %
sides	2-sided
lower limit	11.11
upper limit	26.73

Notes:

[9] - P-value from Cochran-Mantel-Haenszel (CMH) test stratified

[10] - 1-sided p-value

<b>Statistical analysis title</b>	Complete response rate (CRR)
Statistical analysis description:	
At primary completion date	
Comparison groups	Copanlisib + Rituximab v Placebo + Rituximab
Number of subjects included in analysis	458
Analysis specification	Pre-specified
Analysis type	superiority <sup>[11]</sup>
P-value	< 0.000001 <sup>[12]</sup>
Method	Logrank
Parameter estimate	Difference in CRR
Point estimate	19.27
Confidence interval	
level	95 %
sides	2-sided
lower limit	11.57
upper limit	26.96

Notes:

[11] - P-value from Cochran-Mantel-Haenszel (CMH) test stratified.

[12] - 1-sided p-value

### Secondary: Duration of response (DOR)

End point title	Duration of response (DOR)
End point description:	
Duration of response (DOR) was defined as the time (in days) from first observed tumor response Complete Response (CR), Very good partial response (VGPR), Partial Response (PR) or Minor Response (MR) until progression or death from any cause, whichever occurred earlier according to the Owen Criteria. Only patients with response in FAS were included in the analysis.	
End point type	Secondary
End point timeframe:	
From first subject randomization up to approximately 7 years at data cut-off date	

End point values	Copanlisib + Rituximab	Placebo + Rituximab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	307	151		
Units: Months				
median (confidence interval 95%)				
At primary completion date	20.4 (17.0 to 30.8)	17.3 (11.8 to 25.3)		
At 2-year follow-up cut-off date	25.9 (17.7 to 31.5)	15.2 (12.3 to 25.3)		

### Statistical analyses

<b>Statistical analysis title</b>	Duration of response (DOR)
Statistical analysis description: At 2-year follow-up cut-off date	
Comparison groups	Copanlisib + Rituximab v Placebo + Rituximab
Number of subjects included in analysis	458
Analysis specification	Pre-specified
Analysis type	superiority <sup>[13]</sup>
P-value	= 0.051976 <sup>[14]</sup>
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.761
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.547
upper limit	1.059

Notes:

[13] - DOR was evaluated with the stratified log-rank test. HR and 95% CI were based on stratified Cox Regression Model.

[14] - 1-sided p-value

<b>Statistical analysis title</b>	Duration of response (DOR)
Statistical analysis description: At primary completion date	
Comparison groups	Copanlisib + Rituximab v Placebo + Rituximab
Number of subjects included in analysis	458
Analysis specification	Pre-specified
Analysis type	superiority <sup>[15]</sup>
P-value	= 0.058262 <sup>[16]</sup>
Method	Logrank
Parameter estimate	Difference in DOR
Point estimate	0.741
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.508
upper limit	1.079

Notes:

[15] - DOR was evaluated with the stratified log-rank test. HR and 95% CI were based on stratified Cox Regression Model.

[16] - 1-sided p-value

### Secondary: Disease control rate (DCR)

End point title	Disease control rate (DCR)
End point description: Disease control rate was defined as the percentage of subjects who had a best response rating as Complete Response (CR), Partial Response (PR) or stable disease (SD) according to the Lugano Classification and for patients with Waldenström macroglobulinemia (WM) as a response rating of CR, very good partial response (VGPR), PR, minor response (MR) or stable disease (SD) according to the Owen Criteria.	
End point type	Secondary
End point timeframe: From first subject randomization up to approximately 7 years at data cut-off date	

<b>End point values</b>	Copanlisib + Rituximab	Placebo + Rituximab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	307	151		
Units: Percentage of subjects				
number (not applicable)				
At primary completion date	89.3	84.8		
At 2-year follow-up cut-off date	89.3	84.8		

## Statistical analyses

<b>Statistical analysis title</b>	Disease control rate (DCR)
Statistical analysis description: At 2-year follow-up cut-off date	
Comparison groups	Copanlisib + Rituximab v Placebo + Rituximab
Number of subjects included in analysis	458
Analysis specification	Pre-specified
Analysis type	superiority <sup>[17]</sup>
P-value	= 0.097339 <sup>[18]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in DCR
Point estimate	4.43
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.26
upper limit	11.12

Notes:

[17] - P-value from Cochran-Mantel-Haenszel (CMH) test stratified

[18] - 1-sided p-value

<b>Statistical analysis title</b>	Disease control rate (DCR)
Statistical analysis description: At primary completion date	
Comparison groups	Copanlisib + Rituximab v Placebo + Rituximab
Number of subjects included in analysis	458
Analysis specification	Pre-specified
Analysis type	superiority <sup>[19]</sup>
P-value	= 0.097339 <sup>[20]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in DCR
Point estimate	4.43

Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.26
upper limit	11.12

Notes:

[19] - P-value from Cochran-Mantel-Haenszel (CMH) test stratified

[20] - 1-sided p-value

### Secondary: Time to progression (TTP)

End point title	Time to progression (TTP)
End point description:	
Time to progression (TTP) was defined as the time (days) from date of randomization to date of first observed disease progression according to the Lugano Classification and Response criteria in patients affected by Waldenström macroglobulinemia.	
End point type	Secondary
End point timeframe:	
From first subject randomization up to approximately 7 years at data cut-off date	

End point values	Copanlisib + Rituximab	Placebo + Rituximab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	307	151		
Units: Months				
median (confidence interval 95%)				
At primary completion date	22.3 (19.4 to 33.2)	13.8 (10.8 to 18.7)		
At 2-year follow-up cut-off date	27.7 (21.9 to 33.3)	13.8 (11.0 to 18.7)		

### Statistical analyses

Statistical analysis title	Time to progression (TTP)
Statistical analysis description:	
At primary completion date	
Comparison groups	Copanlisib + Rituximab v Placebo + Rituximab
Number of subjects included in analysis	458
Analysis specification	Pre-specified
Analysis type	superiority <sup>[21]</sup>
P-value	< 0.000001 <sup>[22]</sup>
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.476
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.357
upper limit	0.635

Notes:

[21] - TTP was evaluated with the stratified log-rank test. HR and 95% CI were based on Cox Regression Model.

[22] - 1-sided p-value

<b>Statistical analysis title</b>	Time to progression (TTP)
Statistical analysis description: At 2-year follow-up cut-off date	
Comparison groups	Copanlisib + Rituximab v Placebo + Rituximab
Number of subjects included in analysis	458
Analysis specification	Pre-specified
Analysis type	superiority <sup>[23]</sup>
P-value	< 0.000001 <sup>[24]</sup>
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.505
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.387
upper limit	0.659

Notes:

[23] - TTP was evaluated with the stratified log-rank test. HR and 95% CI were based on Cox Regression Model.

[24] - 1-sided p-value

### Secondary: Overall survival (OS) till Primary Completion date.

End point title	Overall survival (OS) till Primary Completion date.
End point description: Overall survival (OS) was defined as the time (in days) from randomization until death from any cause.	
End point type	Secondary
End point timeframe: From randomization to 31-Aug-2020.	

End point values	Copanlisib + Rituximab	Placebo + Rituximab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	307 <sup>[25]</sup>	151 <sup>[26]</sup>		
Units: Months				
median (confidence interval 95%)	57.4 (-99999 to 99999)	99999 (-99999 to 99999)		

Notes:

[25] - 99999 - value cannot be estimated due to censored data (insufficient number of events).

[26] - 99999 - value cannot be estimated due to censored data (insufficient number of events).

### Statistical analyses

<b>Statistical analysis title</b>	Overall survival (OS)
Comparison groups	Copanlisib + Rituximab v Placebo + Rituximab

Number of subjects included in analysis	458
Analysis specification	Pre-specified
Analysis type	superiority <sup>[27]</sup>
P-value	= 0.597747 <sup>[28]</sup>
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.628
upper limit	1.821

Notes:

[27] - OS was evaluated with the stratified log-rank test. HR and 95% CI were based on Cox Regression Model.

[28] - 1-sided p-value

**Secondary: Time to deterioration in DRS-P (Disease-Related Symptoms – Physical) of at least three points, as measured by the Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (FLymSI-18) questionnaire.**

End point title	Time to deterioration in DRS-P (Disease-Related Symptoms – Physical) of at least three points, as measured by the Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (FLymSI-18) questionnaire.
-----------------	--

End point description:

Time to deterioration in DRS-P (Disease-Related Symptoms – Physical) of at least three points was defined as the time (in days) from randomization to DRS-P decline, progression, or death due to any reason, whichever occurred earlier. The Lymphoma Symptom Index-18 (FLymSI-18) questionnaire contains 18 items, each of which utilizes a Likert scale with 5 possible responses ranging from 0 'Not at all' to 4 'Very much' and was divided into a total score.

End point type	Secondary
----------------	-----------

End point timeframe:

From first subject randomization up to approximately 7 years at data cut-off date

<b>End point values</b>	Copanlisib + Rituximab	Placebo + Rituximab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	307	151		
Units: Months				
median (confidence interval 95%)				
At primary completion date	5.5 (4.2 to 5.9)	5.5 (4.0 to 7.4)		
At 2-year follow-up cut-off date	5.5 (4.2 to 5.9)	5.5 (4.1 to 7.4)		

**Statistical analyses**

<b>Statistical analysis title</b>	Time to deterioration in DRS-P
-----------------------------------	--------------------------------

Statistical analysis description:

At 2-year follow-up cut-off date

Comparison groups	Copanlisib + Rituximab v Placebo + Rituximab
-------------------	--

Number of subjects included in analysis	458
Analysis specification	Pre-specified
Analysis type	superiority <sup>[29]</sup>
P-value	= 0.661145 <sup>[30]</sup>
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.047
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.841
upper limit	1.302

Notes:

[29] - Time to deterioration in DRS-P was evaluated with the stratified log-rank test. HR and 95% CI were based on Cox Regression Model.

[30] - 1-sided p-value

<b>Statistical analysis title</b>	Time to deterioration in DRS-P
Statistical analysis description:	
At primary completion date	
Comparison groups	Copanlisib + Rituximab v Placebo + Rituximab
Number of subjects included in analysis	458
Analysis specification	Pre-specified
Analysis type	superiority <sup>[31]</sup>
P-value	= 0.69261 <sup>[32]</sup>
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.843
upper limit	1.331

Notes:

[31] - Time to deterioration in DRS-P was evaluated with the stratified log-rank test. HR and 95% CI were based on Cox Regression Model.

[32] - 1-sided p-value

**Secondary: Time to improvement in DRS-P (Disease-Related Symptoms – Physical) of at least 3 points, as measured by the Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (FLyMSI-18) questionnaire.**

End point title	Time to improvement in DRS-P (Disease-Related Symptoms – Physical) of at least 3 points, as measured by the Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (FLyMSI-18) questionnaire.
-----------------	--

End point description:

Time to improvement in DRS-P (Disease-Related Symptoms – Physical) was defined as the time (in days) from randomization to DRS-P improvement of at least three points. The Lymphoma Symptom Index-18 (FLyMSI-18) questionnaire contains 18 items, each of which utilizes a Likert scale with 5 possible responses ranging from 0 'Not at all' to 4 'Very much' and was divided into a total score.

End point type	Secondary
----------------	-----------

End point timeframe:

From first subject randomization up to approximately 7 years at data cut-off date

<b>End point values</b>	Copanlisib + Rituximab	Placebo + Rituximab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	307 <sup>[33]</sup>	151 <sup>[34]</sup>		
Units: Months				
median (confidence interval 95%)				
At primary completion date	99999 (8.3 to 99999)	99999 (6.0 to 99999)		
At 2-year follow-up cut-off date	38.5 (8.2 to 99999)	35.7 (5.9 to 99999)		

Notes:

[33] - 99999 - value cannot be estimated due to censored data (insufficient number of events).

[34] - 99999 - value cannot be estimated due to censored data (insufficient number of events).

### Statistical analyses

<b>Statistical analysis title</b>	Time to improvement in DRS-P
Statistical analysis description:	
At primary completion date	
Comparison groups	Copanlisib + Rituximab v Placebo + Rituximab
Number of subjects included in analysis	458
Analysis specification	Pre-specified
Analysis type	superiority <sup>[35]</sup>
P-value	= 0.510038 <sup>[36]</sup>
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.996
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.732
upper limit	1.355

Notes:

[35] - Time to improvement in DRS-P was evaluated with the stratified log-rank test. HR and 95% CI were based on Cox Regression Model.

[36] - 1-sided p-value

<b>Statistical analysis title</b>	Time to improvement in DRS-P
Statistical analysis description:	
At 2-year follow-up cut-off date	
Comparison groups	Copanlisib + Rituximab v Placebo + Rituximab
Number of subjects included in analysis	458
Analysis specification	Pre-specified
Analysis type	superiority <sup>[37]</sup>
P-value	= 0.40597 <sup>[38]</sup>
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.036

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.768
upper limit	1.398

Notes:

[37] - Time to improvement in DRS-P was evaluated with the stratified log-rank test. HR and 95% CI were based on Cox Regression Model.

[38] - 1-sided p-value

---

**Secondary: Number of subjects with treatment-emergent adverse events (TEAEs) at primary completion date.**

End point title	Number of subjects with treatment-emergent adverse events (TEAEs) at primary completion date.
-----------------	---

End point description:

Adverse events were considered to be treatment-emergent if they have started or worsened after first application of study medication up to 30 days after end of treatment with study medication.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 30 days after end of treatment with study drug, data reporting cut-off at 5 years from the first subject randomization date

End point values	Copanlisib + Rituximab	Placebo + Rituximab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	307	146		
Units: Subjects				
Any TEAEs	307	134		
Any copanlisib- or placebo-related TEAE	293	95		
Any rituximab-related TEAE	218	92		

**Statistical analyses**

No statistical analyses for this end point

---

**Secondary: Number of subjects with treatment-emergent adverse events (TEAEs) at 2-year follow-up cut-off date.**

End point title	Number of subjects with treatment-emergent adverse events (TEAEs) at 2-year follow-up cut-off date.
-----------------	---

End point description:

Adverse events were considered to be treatment-emergent if they have started or worsened after first application of study medication up to 30 days after end of treatment with study medication.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 30 days after end of treatment with study drug, data reporting cut-off at 7 years from the first subject randomization date

<b>End point values</b>	Copanlisib + Rituximab	Placebo + Rituximab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	307	146		
Units: Subjects				
Any TEAEs	307	137		
Any copanlisib- or placebo-related TEAE	295	98		
Any rituximab-related TEAE	218	93		

### Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From first administration of study drug until 30 days after the last study drug intake includes serious and non-serious adverse events / Time frame for number of death (all causes) - Up to 7 years.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	25.0
--------------------	------

### Reporting groups

Reporting group title	Placebo + Rituximab
-----------------------	---------------------

Reporting group description:

Placebo was administered intravenously (IV) (over approximately 1 h) on Days 1, 8, and 15 of each 28-day cycle. Rituximab (375 mg/m<sup>2</sup>) was administered weekly during Cycle 1 on Days 1, 8, 15, and 22, and then on Day 1 of Cycles 3, 5, 7, and 9. Placebo was administered before rituximab.

Reporting group title	Copanlisib + Rituximab
-----------------------	------------------------

Reporting group description:

Copanlisib (60 mg) was administered intravenously (IV) (over approximately 1 h) on Days 1, 8, and 15 of each 28-day cycle. Rituximab (375 mg/m<sup>2</sup>) was administered weekly during Cycle 1 on Days 1, 8, 15, and 22, and then on Day 1 of Cycles 3, 5, 7, and 9. Copanlisib was administered before rituximab.

<b>Serious adverse events</b>	Placebo + Rituximab	Copanlisib + Rituximab	
Total subjects affected by serious adverse events			
subjects affected / exposed	32 / 146 (21.92%)	161 / 307 (52.44%)	
number of deaths (all causes)	42	78	
number of deaths resulting from adverse events	1	9	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Colorectal adenoma			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer			
subjects affected / exposed	0 / 146 (0.00%)	3 / 307 (0.98%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tumour pain			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Squamous cell carcinoma of skin subjects affected / exposed	1 / 146 (0.68%)	0 / 307 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma subjects affected / exposed	1 / 146 (0.68%)	0 / 307 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basosquamous carcinoma subjects affected / exposed	1 / 146 (0.68%)	0 / 307 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal cell carcinoma subjects affected / exposed	1 / 146 (0.68%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma gastric subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Thrombosis			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep vein thrombosis			
subjects affected / exposed	0 / 146 (0.00%)	2 / 307 (0.65%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			

subjects affected / exposed	0 / 146 (0.00%)	4 / 307 (1.30%)	
occurrences causally related to treatment / all	0 / 0	5 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Surgical and medical procedures</b>			
<b>Arthrodesis</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Central venous catheterisation</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Ureteral stent removal</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Inguinal hernia repair</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>General disorders and administration site conditions</b>			
<b>Generalised oedema</b>			
subjects affected / exposed	1 / 146 (0.68%)	0 / 307 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Fatigue</b>			
subjects affected / exposed	0 / 146 (0.00%)	2 / 307 (0.65%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Death</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	

Asthenia			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mucosal inflammation			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Administration site extravasation			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	0 / 146 (0.00%)	5 / 307 (1.63%)	
occurrences causally related to treatment / all	0 / 0	3 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaphylactic reaction			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Uterine prolapse			
subjects affected / exposed	1 / 146 (0.68%)	0 / 307 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Respiratory, thoracic and mediastinal disorders			
Haemoptysis			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	1 / 146 (0.68%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis chronic			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Idiopathic interstitial pneumonia			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	0 / 146 (0.00%)	2 / 307 (0.65%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	1 / 1	
Pulmonary embolism			
subjects affected / exposed	0 / 146 (0.00%)	4 / 307 (1.30%)	
occurrences causally related to treatment / all	0 / 0	4 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonitis			
subjects affected / exposed	0 / 146 (0.00%)	15 / 307 (4.89%)	
occurrences causally related to treatment / all	0 / 0	15 / 15	
deaths causally related to treatment / all	0 / 0	1 / 1	

Pleural effusion			
subjects affected / exposed	4 / 146 (2.74%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	1 / 6	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Interstitial lung disease			
subjects affected / exposed	0 / 146 (0.00%)	6 / 307 (1.95%)	
occurrences causally related to treatment / all	0 / 0	6 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Neutrophil count decreased			
subjects affected / exposed	1 / 146 (0.68%)	5 / 307 (1.63%)	
occurrences causally related to treatment / all	1 / 1	6 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood calcium increased			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Amylase increased			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza A virus test positive			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lipase increased			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Stoma site haemorrhage			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Transfusion-related acute lung injury			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infusion related reaction			
subjects affected / exposed	1 / 146 (0.68%)	0 / 307 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal fracture			
subjects affected / exposed	0 / 146 (0.00%)	2 / 307 (0.65%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dislocation of vertebra			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Eustachian valve hypertrophy			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular extrasystoles			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular arrhythmia			

subjects affected / exposed	1 / 146 (0.68%)	0 / 307 (0.00%)	
occurrences causally related to treatment / all	3 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Myocardial infarction</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Nervous system disorders</b>			
<b>Cerebral haemorrhage</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cerebral infarction</b>			
subjects affected / exposed	1 / 146 (0.68%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cerebrovascular accident</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>IIIrd nerve paralysis</b>			
subjects affected / exposed	1 / 146 (0.68%)	0 / 307 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Seizure like phenomena</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Ischaemic stroke</b>			
subjects affected / exposed	1 / 146 (0.68%)	0 / 307 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Tension headache</b>			

subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Syncope</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Peripheral sensory neuropathy</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Neuralgia</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Blood and lymphatic system disorders</b>			
<b>Febrile neutropenia</b>			
subjects affected / exposed	3 / 146 (2.05%)	4 / 307 (1.30%)	
occurrences causally related to treatment / all	2 / 3	6 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Myelosuppression</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Neutropenia</b>			
subjects affected / exposed	0 / 146 (0.00%)	2 / 307 (0.65%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Immune thrombocytopenia</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Anaemia</b>			

subjects affected / exposed	1 / 146 (0.68%)	3 / 307 (0.98%)	
occurrences causally related to treatment / all	0 / 2	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gastrointestinal disorders</b>			
<b>Diarrhoea</b>			
subjects affected / exposed	0 / 146 (0.00%)	2 / 307 (0.65%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Enteritis</b>			
subjects affected / exposed	0 / 146 (0.00%)	2 / 307 (0.65%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Enterocolitis</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
<b>Haemorrhoids</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Incarcerated inguinal hernia</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Nausea</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Vomiting</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Colitis microscopic</b>			

subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gastrointestinal toxicity</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Colitis</b>			
subjects affected / exposed	0 / 146 (0.00%)	2 / 307 (0.65%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Abdominal incarcerated hernia</b>			
subjects affected / exposed	1 / 146 (0.68%)	0 / 307 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Anal fissure</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Hepatobiliary disorders</b>			
<b>Hepatitis acute</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cholecystitis</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Biliary colic</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Bile duct stone</b>			

subjects affected / exposed	1 / 146 (0.68%)	0 / 307 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Skin and subcutaneous tissue disorders</b>			
Panniculitis			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis exfoliative generalised			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Renal and urinary disorders</b>			
Acute kidney injury			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydronephrosis			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus urinary			
subjects affected / exposed	1 / 146 (0.68%)	0 / 307 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Infections and infestations</b>			
Atypical pneumonia			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Bronchiolitis			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	0 / 146 (0.00%)	2 / 307 (0.65%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile colitis			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis bacterial			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary tuberculosis			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia viral			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia mycoplasmal			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia cytomegaloviral			
subjects affected / exposed	1 / 146 (0.68%)	0 / 307 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			

subjects affected / exposed	5 / 146 (3.42%)	22 / 307 (7.17%)
occurrences causally related to treatment / all	4 / 5	15 / 25
deaths causally related to treatment / all	0 / 0	0 / 1
Parvovirus B19 infection		
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Oral candidiasis		
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Lower respiratory tract infection		
subjects affected / exposed	1 / 146 (0.68%)	3 / 307 (0.98%)
occurrences causally related to treatment / all	1 / 1	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0
Herpes zoster		
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Gastroenteritis		
subjects affected / exposed	0 / 146 (0.00%)	4 / 307 (1.30%)
occurrences causally related to treatment / all	0 / 0	2 / 4
deaths causally related to treatment / all	0 / 0	0 / 0
Enterococcal bacteraemia		
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Bronchitis		
subjects affected / exposed	1 / 146 (0.68%)	2 / 307 (0.65%)
occurrences causally related to treatment / all	0 / 1	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Sinusitis		

subjects affected / exposed	1 / 146 (0.68%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Subcutaneous abscess</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Upper respiratory tract infection</b>			
subjects affected / exposed	0 / 146 (0.00%)	2 / 307 (0.65%)	
occurrences causally related to treatment / all	0 / 0	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Urinary tract infection</b>			
subjects affected / exposed	2 / 146 (1.37%)	4 / 307 (1.30%)	
occurrences causally related to treatment / all	0 / 2	2 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Viral infection</b>			
subjects affected / exposed	0 / 146 (0.00%)	2 / 307 (0.65%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Urosepsis</b>			
subjects affected / exposed	1 / 146 (0.68%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Anal abscess</b>			
subjects affected / exposed	0 / 146 (0.00%)	2 / 307 (0.65%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Neutropenic sepsis</b>			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Muscle abscess</b>			

subjects affected / exposed	1 / 146 (0.68%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Escherichia urinary tract infection		
subjects affected / exposed	1 / 146 (0.68%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Cytomegalovirus infection reactivation		
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Pneumonia bacterial		
subjects affected / exposed	2 / 146 (1.37%)	4 / 307 (1.30%)
occurrences causally related to treatment / all	2 / 3	3 / 5
deaths causally related to treatment / all	0 / 1	0 / 0
Atypical mycobacterial infection		
subjects affected / exposed	1 / 146 (0.68%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Penile infection		
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Respiratory tract infection viral		
subjects affected / exposed	1 / 146 (0.68%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Respiratory tract infection		
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)
occurrences causally related to treatment / all	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
COVID-19 pneumonia		

subjects affected / exposed	0 / 146 (0.00%)	2 / 307 (0.65%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19			
subjects affected / exposed	2 / 146 (1.37%)	8 / 307 (2.61%)	
occurrences causally related to treatment / all	0 / 2	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 3	
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	0 / 146 (0.00%)	8 / 307 (2.61%)	
occurrences causally related to treatment / all	0 / 0	7 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related infection			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Diabetes mellitus			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tumour lysis syndrome			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	0 / 146 (0.00%)	1 / 307 (0.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	0 / 146 (0.00%)	21 / 307 (6.84%)	
occurrences causally related to treatment / all	0 / 0	27 / 27	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercalcaemia			

subjects affected / exposed	1 / 146 (0.68%)	0 / 307 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Placebo + Rituximab	Copanlisib + Rituximab
Total subjects affected by non-serious adverse events		
subjects affected / exposed	126 / 146 (86.30%)	297 / 307 (96.74%)
Investigations		
Blood cholesterol increased		
subjects affected / exposed	8 / 146 (5.48%)	13 / 307 (4.23%)
occurrences (all)	15	14
Blood bilirubin increased		
subjects affected / exposed	2 / 146 (1.37%)	16 / 307 (5.21%)
occurrences (all)	4	31
Aspartate aminotransferase increased		
subjects affected / exposed	12 / 146 (8.22%)	28 / 307 (9.12%)
occurrences (all)	22	37
Amylase increased		
subjects affected / exposed	4 / 146 (2.74%)	16 / 307 (5.21%)
occurrences (all)	13	20
Alanine aminotransferase increased		
subjects affected / exposed	11 / 146 (7.53%)	30 / 307 (9.77%)
occurrences (all)	20	46
Blood creatine phosphokinase increased		
subjects affected / exposed	7 / 146 (4.79%)	25 / 307 (8.14%)
occurrences (all)	11	41
White blood cell count decreased		
subjects affected / exposed	17 / 146 (11.64%)	61 / 307 (19.87%)
occurrences (all)	53	313
Weight decreased		
subjects affected / exposed	4 / 146 (2.74%)	46 / 307 (14.98%)
occurrences (all)	5	66
Platelet count decreased		

subjects affected / exposed occurrences (all)	12 / 146 (8.22%) 23	42 / 307 (13.68%) 121	
Neutrophil count decreased subjects affected / exposed occurrences (all)	34 / 146 (23.29%) 74	101 / 307 (32.90%) 433	
Lymphocyte count decreased subjects affected / exposed occurrences (all)	9 / 146 (6.16%) 38	42 / 307 (13.68%) 122	
Lipase increased subjects affected / exposed occurrences (all)	4 / 146 (2.74%) 12	18 / 307 (5.86%) 37	
<b>Vascular disorders</b>			
Hypertension subjects affected / exposed occurrences (all)	31 / 146 (21.23%) 119	156 / 307 (50.81%) 777	
<b>Nervous system disorders</b>			
Dizziness subjects affected / exposed occurrences (all)	6 / 146 (4.11%) 6	16 / 307 (5.21%) 19	
Headache subjects affected / exposed occurrences (all)	10 / 146 (6.85%) 20	43 / 307 (14.01%) 71	
Dysgeusia subjects affected / exposed occurrences (all)	2 / 146 (1.37%) 2	21 / 307 (6.84%) 28	
<b>Blood and lymphatic system disorders</b>			
Neutropenia subjects affected / exposed occurrences (all)	24 / 146 (16.44%) 57	64 / 307 (20.85%) 243	
Anaemia subjects affected / exposed occurrences (all)	16 / 146 (10.96%) 61	59 / 307 (19.22%) 137	
<b>General disorders and administration site conditions</b>			
Asthenia subjects affected / exposed occurrences (all)	5 / 146 (3.42%) 7	21 / 307 (6.84%) 27	

Chills			
subjects affected / exposed	7 / 146 (4.79%)	22 / 307 (7.17%)	
occurrences (all)	10	33	
Fatigue			
subjects affected / exposed	11 / 146 (7.53%)	44 / 307 (14.33%)	
occurrences (all)	16	51	
Influenza like illness			
subjects affected / exposed	6 / 146 (4.11%)	16 / 307 (5.21%)	
occurrences (all)	9	18	
Mucosal inflammation			
subjects affected / exposed	2 / 146 (1.37%)	18 / 307 (5.86%)	
occurrences (all)	2	23	
Pyrexia			
subjects affected / exposed	14 / 146 (9.59%)	61 / 307 (19.87%)	
occurrences (all)	21	93	
Gastrointestinal disorders			
Vomiting			
subjects affected / exposed	5 / 146 (3.42%)	44 / 307 (14.33%)	
occurrences (all)	5	61	
Nausea			
subjects affected / exposed	17 / 146 (11.64%)	70 / 307 (22.80%)	
occurrences (all)	25	116	
Mouth ulceration			
subjects affected / exposed	4 / 146 (2.74%)	20 / 307 (6.51%)	
occurrences (all)	6	29	
Diarrhoea			
subjects affected / exposed	15 / 146 (10.27%)	105 / 307 (34.20%)	
occurrences (all)	19	244	
Constipation			
subjects affected / exposed	12 / 146 (8.22%)	31 / 307 (10.10%)	
occurrences (all)	14	37	
Abdominal pain			
subjects affected / exposed	5 / 146 (3.42%)	17 / 307 (5.54%)	
occurrences (all)	6	23	
Stomatitis			

subjects affected / exposed occurrences (all)	4 / 146 (2.74%) 9	41 / 307 (13.36%) 58	
Respiratory, thoracic and mediastinal disorders			
Oropharyngeal pain			
subjects affected / exposed	6 / 146 (4.11%)	18 / 307 (5.86%)	
occurrences (all)	7	21	
Dyspnoea			
subjects affected / exposed	14 / 146 (9.59%)	17 / 307 (5.54%)	
occurrences (all)	18	17	
Cough			
subjects affected / exposed	19 / 146 (13.01%)	47 / 307 (15.31%)	
occurrences (all)	30	69	
Skin and subcutaneous tissue disorders			
Rash maculo-papular			
subjects affected / exposed	3 / 146 (2.05%)	21 / 307 (6.84%)	
occurrences (all)	4	33	
Rash			
subjects affected / exposed	10 / 146 (6.85%)	35 / 307 (11.40%)	
occurrences (all)	13	50	
Pruritus			
subjects affected / exposed	9 / 146 (6.16%)	30 / 307 (9.77%)	
occurrences (all)	12	39	
Dry skin			
subjects affected / exposed	2 / 146 (1.37%)	20 / 307 (6.51%)	
occurrences (all)	2	22	
Psychiatric disorders			
Insomnia			
subjects affected / exposed	5 / 146 (3.42%)	18 / 307 (5.86%)	
occurrences (all)	5	19	
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	13 / 146 (8.90%)	19 / 307 (6.19%)	
occurrences (all)	17	21	
Muscle spasms			
subjects affected / exposed	2 / 146 (1.37%)	19 / 307 (6.19%)	
occurrences (all)	2	26	

Myalgia			
subjects affected / exposed	11 / 146 (7.53%)	8 / 307 (2.61%)	
occurrences (all)	12	10	
Pain in extremity			
subjects affected / exposed	5 / 146 (3.42%)	18 / 307 (5.86%)	
occurrences (all)	6	25	
Arthralgia			
subjects affected / exposed	9 / 146 (6.16%)	21 / 307 (6.84%)	
occurrences (all)	15	24	
Infections and infestations			
Pneumonia			
subjects affected / exposed	12 / 146 (8.22%)	35 / 307 (11.40%)	
occurrences (all)	15	53	
Bronchitis			
subjects affected / exposed	8 / 146 (5.48%)	18 / 307 (5.86%)	
occurrences (all)	9	25	
Influenza			
subjects affected / exposed	11 / 146 (7.53%)	8 / 307 (2.61%)	
occurrences (all)	13	9	
Nasopharyngitis			
subjects affected / exposed	7 / 146 (4.79%)	28 / 307 (9.12%)	
occurrences (all)	12	41	
COVID-19			
subjects affected / exposed	4 / 146 (2.74%)	16 / 307 (5.21%)	
occurrences (all)	4	19	
Oral herpes			
subjects affected / exposed	4 / 146 (2.74%)	19 / 307 (6.19%)	
occurrences (all)	5	29	
Urinary tract infection			
subjects affected / exposed	13 / 146 (8.90%)	37 / 307 (12.05%)	
occurrences (all)	20	65	
Upper respiratory tract infection			
subjects affected / exposed	27 / 146 (18.49%)	57 / 307 (18.57%)	
occurrences (all)	35	114	
Metabolism and nutrition disorders			

Hypokalaemia		
subjects affected / exposed	1 / 146 (0.68%)	24 / 307 (7.82%)
occurrences (all)	2	37
Hyperuricaemia		
subjects affected / exposed	8 / 146 (5.48%)	19 / 307 (6.19%)
occurrences (all)	18	32
Hypertriglyceridaemia		
subjects affected / exposed	7 / 146 (4.79%)	21 / 307 (6.84%)
occurrences (all)	23	36
Hyperglycaemia		
subjects affected / exposed	35 / 146 (23.97%)	210 / 307 (68.40%)
occurrences (all)	92	939
Decreased appetite		
subjects affected / exposed	4 / 146 (2.74%)	23 / 307 (7.49%)
occurrences (all)	4	28

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
23 January 2015	- The study target population for the efficacy analysis was changed from iNHL patients to FL patients. - The randomization ratio was changed from 1:1 to 2:1 and the stratification factors were changed. - Time to improvement in DRS-P was added as a secondary efficacy variable.
18 February 2016	- The conservative requirement for blood pressure levels during the evaluation of patient's eligibility was removed due to feedback from the investigators and lymphoma specialists. - A requirement for prophylactic antiviral therapy to be given to patients who are positive for HBsAg or HBcAb at screening was added. - Copanlisib was added to the list of prohibited previous therapies and medications.
28 July 2016	- Guidance on dose modification of copanlisib or placebo for hematological toxicity was updated. - Following Health Authority alerts related to safety issues with Zydelig (idelalisib, a PI3K inhibitor) treatment in clinical trials, text was added to provide guidance for monitoring and prophylaxis of opportunistic infections in patients who are at risk for opportunistic infection development while on study treatment.
02 February 2018	- The total sample size was reduced from 567 patients to 450 patients and the primary efficacy analysis was revised to be performed in the FAS instead of both the FAS and FL subpopulation. - Patients considered unwilling/unfit to receive chemotherapy were bundled to differentiate them in a subgroup different from the long-term responders (i.e., progression-free and treatment-free interval of $\geq 12$ months after completion of the last rituximab-containing treatment).
08 October 2019	- The statistical assumptions for the primary efficacy analysis of PFS were modified. The required number of PFS events was changed from 288 to 190. - The confirmatory testing strategy was modified.
22 May 2020	- Number of events necessary for primary completion analyses was changed to "at least 190 PFS events" to remain flexible. - Removed potential pooling of strata. In order to avoid a too low number of events, only stratification factors "iNHL histology" and "entry criterion" will be adjusted simultaneously in the statistical analyses. - Confirmatory statistical testing strategy for the US was revised and an additional confirmatory statistical testing strategy for the EU was added.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The Overall Survival analysis is very immature due to the low number of events. In Subject disposition section, the number of subjects for Completed were ongoing with treatment.

Notes:

---

## Online references

<http://www.ncbi.nlm.nih.gov/pubmed/33848462>